Analysis of clarithromycin potential adverse drug interactions and establishment of refined prescription pre-review rules
- VernacularTitle:克拉霉素潜在不良药物相互作用分析及精细化前置审方规则建立
- Author:
Long WANG
1
;
Li ZHANG
2
;
Lingna ZHU
1
;
Guanjun ZHANG
1
;
Jun CHENG
1
Author Information
1. Dept. of Pharmacy，the Third People’s Hospital of Bengbu，Anhui Bengbu 233099，China
2. Dept. of Pharmacy，the Second Affiliated Hospital of Bengbu Medical University，Anhui Bengbu 233004，China
- Publication Type:Journal Article
- Keywords:
clarithromycin;
potential adverse drug interactions;
prescription pre-review
- From:
China Pharmacy
2025;36(8):986-990
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To analyze the potential adverse drug interactions （pADIs） of clarithromycin， and establish refined prescription pre-review rules. METHODS Outpatient prescriptions of clarithromycin in combination with other drugs were collected from January 1， 2024 to June 30， 2024 through hospital information system of the Third People’s Hospital of Bengbu. pADIs were identified and their risk severities were graded according to Lexicomp and Micromedex databases. Then， refined prescription pre- review rules for clarithromycin pADIs-related drugs were established according to the identification and risk level results. RESULTS Among 3 046 clarithromycin combined drug prescriptions， 946 cases of pADIs occurred in 812 prescriptions. There were 6， 415 and 525 cases classified as “contraindicated”，“ major” and “moderate”， respectively. The combination drugs with “contraindicated” levels were tamsulosin， rupatadine， domperidone and ticagrelor， while those with “major” levels were mainly theophylline， dexamethasone and amlodipine. Accordingly， 26 refined rules were established， including 4 items of “warning information→prescription interception”， 11 items of “warning information→prescription double signature” and 11 items of “attention information→prescription approval”. CONCLUSIONS There are “contraindicated” and “major” risks associated with clarithromycin and its combination drugs in the hospital， and refined prescription pre-review rules for clarithromycin combined drug prescription have been established successfully.
